Latest Breaking News On - Executive yu xuefeng - Page 1 : comparemela.com

By Reuters Staff BEIJING (Reuters) – China’s CanSino Biologics Inc. has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday. The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy. “As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” said Zheng Zhongwei, an official at China’s National Health Commission, told a press conference. Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. https://bit.ly/3mHzt8R

Roxanne liuDavid evansYu xuefengZheng zhongweiChina national health commissionChina cansino biologics incChinese academy of medical sciencesCansino biologics incNational health commissionExecutive yu xuefengChinese academyMedical sciencesReporting roxanne liuRyan wooரோக்ஷ்ண்னே லியூடேவிட் எவன்ஸ்